High anti-tumor necrosis factor alpha treatment trough concentrations are not associated with higher rate of adverse events in pediatric patients with inflammatory bowel disease

被引：0
|
作者：
Zvuloni, M. [1 ]
Matar, M. [2 ]
Levi, R. [3 ]
Shamir, R. [1 ,2 ]
Assa, A. [2 ,4 ]
机构：
[1] Tel Aviv Univ, Sackler Fac Med, Dept Med, Tel Aviv, Israel
[2] Schneider Childrens Hosp, Inst Gastroenterol Nutr & Liver Dis, Petah Tiqwa, Israel
[3] Schneider Childrens Hosp, Pediat Dept A, Petah Tiqwa, Israel
[4] Ben Gurion Univ Negev, Dept Med, Beer Sheva, Israel
来源：
JOURNAL OF CROHNS & COLITIS | 2021年 / 15卷
关键词：
D O I：
10.1093/ecco-jcc/jjab076.506
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P382
引用
收藏
页码：S395 / S395
页数：1
相关论文
共 50 条
  • [41] Effectiveness and safety of vedolizumab in pediatric inflammatory bowel disease after failure of anti-tumor necrosis factor-alpha therapy
    Khan, R.
    Thacker, K.
    Spargo, M.
    Dutt, S.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 : 201 - 201
  • [42] Anti-tumor Necrosis Factor-alpha Exposure Impacts Vedolizumab Mucosal Healing Rates in Pediatric Inflammatory Bowel Disease
    Jossen, Jacqueline
    Kiernan, Bridget D.
    Pittman, Nanci
    Dubinsky, Marla C.
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2020, 70 (03): : 304 - 309
  • [43] LOW RISK OF LYMPHOMA IN PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED USING ANTI-TUMOR NECROSIS FACTOR AGENTS
    Egberg, Matthew D.
    Smitherman, Andrew
    Zhang, Xian
    Kappelman, Michael
    GASTROENTEROLOGY, 2020, 158 (06) : S968 - S969
  • [44] LOW RISK OF LYMPHOMA IN PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED USING ANTI-TUMOR NECROSIS FACTOR AGENTS
    Egberg, Matthew
    Smitherman, Andrew
    Zhang, Xian
    Kappelman, Michael
    INFLAMMATORY BOWEL DISEASES, 2020, 26 : S2 - S3
  • [45] Benefits and Risks of Combining Anti-tumor Necrosis Factor with Immunomodulator Therapy in Pediatric Inflammatory Bowel Disease
    Cozijnsen, Martinus A.
    Escher, Johanna C.
    Griffiths, Anne
    Turner, Dan
    de Ridder, Lissy
    INFLAMMATORY BOWEL DISEASES, 2015, 21 (04) : 951 - 961
  • [46] Efficacy of iron supplementation in patients with inflammatory bowel disease treated with anti-tumor necrosis factor-alpha agents
    Kim, Su Young
    An, Sejin
    Park, Dong Kyun
    Kwon, Kwang An
    Kim, Kyoung Oh
    Chung, Jun-Won
    Kim, Jung Ho
    Kim, Yoon Jae
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2020, 13
  • [47] Efficacy and Safety of Anti-Tumor Necrosis Factor Alpha in Very Early Onset Inflammatory Bowel Disease
    Collen, Lauren, V
    Mitsialis, Vanessa
    Kim, David Y.
    Bresnahan, Mairead
    Yang, Jessica
    Tuthill, Margaret
    Combs, Abigail
    Barends, Jared
    Field, Michael
    Liu, Enju
    Bearup, Richelle
    Okoroafor, Ibeawuchi
    Klein, Christoph
    Muise, Aleixo M.
    Bousvaros, Athos
    Ouahed, Jodie
    Snapper, Scott B.
    INFLAMMATORY BOWEL DISEASES, 2023, 30 (09) : 1443 - 1453
  • [48] Adverse Events Associated with Azathioprine Treatment in Korean Pediatric Inflammatory Bowel Disease Patients
    Chun, Ji Young
    Kang, Ben
    Lee, Yoo Min
    Lee, Soo Youn
    Kim, Mi Jin
    Choe, Yon Ho
    PEDIATRIC GASTROENTEROLOGY HEPATOLOGY & NUTRITION, 2013, 16 (03) : 171 - 177
  • [49] Adverse events associated with azathioprine treatment in Korean pediatric inflammatory bowel disease patients
    Kim, M.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S280 - S281
  • [50] Should patients with inflammatory bowel disease and depression be given anti-tumor necrosis factor therapy?
    Barnes, A.
    Mountifield, R.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 : 130 - 130
12345